The Barry & Virginia Weinman Symposium

Scientific Image

 
 Hans Clevers, MD, PhD
 
 
 

James E. Cleaver, Ph.D.
 
 
 
 
 

Napoleona Ferrara, M.D.
 
 
 
 

12th & 13th Annual Weinman Award Recipients

The 2022 Weinman Award is given to three distinguished scientists working in the field of cancer cell metabolism:

  • Hans Clevers, MD, PhD.
  • James E. Cleaver, PhD.
  • Napoleone Ferrara, PhD.

 

Hans Clevers, MD, PhD.

Professor of Molecular Genetics, Utrecht University
Utrecht, Holland

"Much of what we know about intestinal physiology and cancer can be attributed to the work of Dr. Clevers and his laboratory...Dr. Clevers was the first to identify stem cells in the intestine and is an authority on cell biology and regenerative therapy. He has been able to grow “mini-intestines” from stem cells, an essential first step toward regenerative medicine. He has been instrumental in establishing a new foundation that will test anti-cancer medicines on living tissues derived from tumors and cultured as mini-organs (organoids). This research is anticipated to lead to the development of a variety of novel drugs capable of being utilized to specifically target the unique genetics of an individual patient’s tumor, technology that holds great promise for the future of precision cancer medicine." (Quote from American Association for Cancer Research)

James E. Cleaver, PhD.

Professor Emeritus of Dermatology and of Pharmaceutical Chemistry
Graduate Program Membership: BMS
UCSF Institute for Human Genetics
San Francisco, USA

Dr. Cleaver focuses on human DNA repair deficient hereditary diseases, especially xeroderma pigmentosum (XP) and Cockayne Syndrome (CS), which present increased solar-induced cancers, and developmental and neurological disorders. (Quote from the University of California San Francisco.)

Napoleone Ferrara, PhD.

Professor of Pathology University of California San Diego (UCSD) San Diego, CA USA
"Napoleone Ferrara, M.D., is currently Distinguished Professor of Pathology and Adjunct Professor of Ophthalmology and Pharmacology. He is also the Hildyard Endowed Chair in Eye Disease. His main research interests are the biology of angiogenesis and the identification of its regulators. In 1989, while at Genentech, Inc., he reported the isolation and cloning of vascular endothelial growth factor (VEGF) and subsequently focused his research on the investigation of the molecular and biological properties of VEGF. These studies established VEGF as a key regulator of normal and pathological angiogenesis. Together with his colleagues, he reported that VEGF inhibition results in suppression of growth of a variety of tumors in vivo. These findings represented the first direct evidence that inhibition of angiogenesis can block tumor growth and led to the development of a humanized anti-VEGF monoclonal antibody (Bevacizumab) as a cancer therapy." (Quote from UCSD website, Napoleone Ferrara, PhD.)